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OBJECTIVE — To compare the effects of a 1-year intervention with a low-carbohydrate and
a low-fat diet on weight loss and glycemic control in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS — This study is a randomized clinical trial of
105overweightadultswithtype2diabetes.PrimaryoutcomeswereweightandA1C.Secondary
outcomes included blood pressure and lipids. Outcome measures were obtained at 3, 6, and 12
months.
RESULTS — The greatest reduction in weight and A1C occurred within the ﬁrst 3 months.
Weightlossoccurredfasterinthelow-carbohydrategroupthaninthelow-fatgroup(P0.005),
but at 1 year a similar 3.4% weight reduction was seen in both dietary groups. There was no
signiﬁcant change in A1C in either group at 1 year. There was no change in blood pressure, but
a greater increase in HDL was observed in the low-carbohydrate group (P  0.002).
CONCLUSIONS — Among patients with type 2 diabetes, after 1 year a low-carbohydrate
diet had effects on weight and A1C similar to those seen with a low-fat diet. There was no
signiﬁcanteffectonbloodpressure,butthelow-carbohydratedietproducedagreaterincreasein
HDL cholesterol.
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T
ype 2 diabetes affects 20 million
people in the U.S. (1). Optimal
weight loss strategies in patients
with type 2 diabetes continue to be de-
bated, and the best dietary strategy to
achieve both weight loss and glycemic
control in type 2 diabetes is unclear.
Prior studies, done primarily in pa-
tients without diabetes, demonstrated
weight loss outcomes with low-
carbohydrate diets comparable to that
withotherdiets(2–6).Basedontheeffec-
tiveness of low-carbohydrate diets for
weight loss, recent guidelines from the
American Diabetes Association state that
for short-term weight loss either a low-
carbohydrate or low-fat calorie-restricted
diet may be effective (7).
In addition to weight loss, the meta-
bolic effects of low-carbohydrate diets
may be of particular beneﬁt in type 2 di-
abetes. Carbohydrates are the primary
source of glucose for metabolism, and re-
stricting carbohydrate intake can reduce
insulinlevels,reducepostprandialhyper-
glycemia, and improve insulin sensitivity
(8,9). In short-term randomized studies
andlong-termobservationalstudies,low-
carbohydrate diets have shown beneﬁts
for improving glycemic control in type 2
diabetes (9–12).
To date, studies examining low-
carbohydrate diets speciﬁcally in patients
with type 2 diabetes have had small sam-
ple sizes, lacked control groups, or had
short follow-up (13). We conducted a
nonblinded, two-arm randomized clini-
cal trial to compare the effects of a 1-year
intervention of a low-carbohydrate diet
with those of a low-fat diet on weight and
glycemic control in overweight patients
with type 2 diabetes. We hypothesized
that a low-carbohydrate diet would result
ingreaterimprovementinweightandgly-
cemic control compared with a low-fat
diet.
RESEARCH DESIGN AND
METHODS— Eligible participants
were adults aged 18 years with a diag-
nosis of type 2 diabetes for at least 6
months, BMI 25 kg/m
2, and A1C be-
tween 6 and 11%. Exclusion criteria were
a weight change of 10 pounds within 3
months of screening, kidney disease (de-
ﬁned as creatinine 1.3 mg/dl), active
liver or gallbladder disease, signiﬁcant
heart disease, a history of severe (requir-
ing hospitalization) hypoglycemia, or use
of weight loss medications. Participants
were recruited from the ofﬁces of primary
carephysicians,endocrinologists,andthe
local community in Bronx, New York,
through physician referral, letters of invi-
tation, and posted advertisements. All
study visits occurred at the Clinical Re-
search Center of Albert Einstein College
of Medicine. The study was approved by
the internal review boards of Albert Ein-
stein College of Medicine and Monteﬁore
Medical Center. All participants provided
written informed consent.
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Studyenrollmentwascompletedbetween
August 2004 and November 2006. As
seen in Fig. 1, 334 individuals responded
to the recruitment effort and 154, who
were eligible, entered a 3- to 4-week
prerandomization protocol. During
prerandomization,participantsreceived
instructions and were asked to complete
dietaryandbloodglucoseself-monitoring
activities. Participants received self-
monitoring supplies that included mea-
suring cups, food scales, and blood
glucose meters with test strips (Ascensia
Elite XL). Forty-nine participants discon-
tinued the study during prerandomiza-
tion, leaving 105 participants who were
randomly assigned.
Dietary interventions
By using a computer-generated 1:1 ran-
domization,participantswereassignedto
either a low-carbohydrate or a low-fat
diet.Thelow-carbohydratedietwasmod-
eled after the Atkins diet (14) and was
initiated with a 2-week phase of carbohy-
draterestrictionof20–25gdailydepend-
ing on baseline weight. As participants
lostweight,theywereabletoincreasecar-
bohydrate intake at 5-g increments each
week. The low-fat diet was modeled after
that in the Diabetes Prevention Program
(15).Participantsreceivedafatgramgoal,
whichwas25%ofenergyneeds,basedon
baseline weight. Participants in each arm
received a booklet with the carbohydrate
or fat content of common foods and in-
structions for self-monitoring. Partici-
pants were responsible for their own food
purchases and food preparation. We pro-
vided participants with general recom-
mendations to achieve 150 min of
physical activity each week, but physical
activity was not an emphasis of the study.
Nutrition counseling
At randomization, all participants re-
ceived 45 min of individual dietary in-
struction by a registered dietitian and
were given a speciﬁc gram allowance of
carbohydrates or fat to achieve a 1-pound
weight loss each week. Structured menus
that provided meal choices and recipes
were used for the ﬁrst 2 weeks (16). After
the ﬁrst 2 weeks, participants were in-
structed on selecting foods that met their
dietary goals without using the menus.
During the 12-month study, participants
had a total of six scheduled, 30-min visits
with the dietitian for additional dietary
counseling.
Medication adjustments
During prerandomization, we adjusted
diabetes medications to minimize side ef-
fects that could affect study ﬁndings, e.g.,
discontinuing thiazolidinediones (due to
weight gain as a side effect) (17) and
changing short-acting insulin to insulin
glargine to minimize the risk of hypogly-
cemia (18). At randomization and during
theremainderofthestudy,weusedapre-
deﬁned algorithm for medication adjust-
ments. The algorithm was developed by
study investigators based on clinical ex-
perience and prior diabetes studies
(19,20) and reviewed by a clinical panel
of experts that included diabetologists,
dietitians, primary care providers, and a
certiﬁed diabetes educator. At random-
ization, the algorithm included reducing
insulin dosages by 50% and discontinu-
ing sulfonylurea in the low-carbohydrate
arm and reducing insulin by 25% and de-
creasing the sulfonylurea dose by 50% in
the low-fat arm. Subsequently, the algo-
rithm for medication adjustment was the
same in both groups. Adjustments of in-
sulin and sulfonylurea were made based
on results of self-monitored capillary
blood glucose. Metformin was not ad-
justed during the study.
Study visits
For the 1st month after randomization,
participants had individual study visits
once or twice weekly and after the 1st
month, participants had scheduled visits
every 6 weeks. During these visits, weight
and blood pressure was measured, and
participants received counseling from the
study staff (study physician and research
assistant), which focused on diabetes
management, adjustment of diabetes
medications, and dietary adherence. As-
certainment of study outcomes was done
during the scheduled study visits closest
to the 3-, 6-, and 12-month time point
after randomization.
Outcomes
Primaryoutcomeswereweightandglyce-
mic control (measured by A1C). In addi-
tion, we collected data on blood pressure
(measured with a manual sphygmoma-
nometer after a 5-min rest period) and
lipids(measuredfromserumsamplescol-
lectedafteranovernightfast).Weightwas
measured with participants in light cloth-
ing and bare feet, using a digital scale
(Tanita BF 681). A1C, total cholesterol,
HDL cholesterol, and triglycerides were
measured by enzymatic immunoassay
(Olympus AU400 chemistry autoana-
lyzer). LDL levels were calculated using
the Friedewald equation (21). All labora-
tory analyses were done in the Clinical
Research Center.
Dietary intake
Atbaseline,6months,and12months,we
collected single-day 24-h recall by in-
person interviews. Participants were also
instructed to keep daily food diaries,
which were reviewed during the study
visits. Because 24-h recall was not col-
Figure 1—Participant ﬂow.
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months, we obtained dietary data for 3
months by analyzing participant food di-
aries for 1 day before their 3-month ap-
pointment. Nutrient data were analyzed
using FoodWorks version 8.01.
Statistical analysis
Means  SD describe the distribution of
baseline variables. Primary outcomes
were 12-month changes in weight and
A1C. Hierarchical linear models were
used to analyze all available data. We ﬁt-
ted a linear spline model, dividing study
time into two phases: an early phase
(months 0–3) and a late phase (months
3–12). Person-level random slopes dur-
ing both phases and intercepts at the per-
sonlevelwereincluded.Treatmentgroup
was represented by an indicator variable,
and coefﬁcients of treatment  time in-
teraction terms were used for inference
about dietary differences. To control for
medication changes, we included the
change in insulin and change in sulfonyl-
urea at each time point as a covariate in
the model with age, sex, and race. Medi-
cation changes were not signiﬁcantly as-
sociated with weight and were dropped
fromtheweightmodel.Theanalyseswere
done with and without imputation of
missing values.
Repeated-measures ANOVAs with
diet as the between-subject factor and
time as the within-subject factor were
used to compare mean changes of blood
pressure and lipids. Unpaired t tests or
Wilcoxon rank tests were used to com-
pare dietary composition at each time
point. For these analyses, we included
only data for which there were results for
all time points.
With a sample size of 105 partici-
pants, we had 80% power to detect a
mean  SD difference in weight of 2.0 
3.3kgandinA1Cof0.71.3%between
dietaryarms.Allstatisticaltestsweretwo-
tailed with a signiﬁcance level of 0.05.
Analyses were done with SPSS 15.0 and
STATA 10.1.
RESULTS— At baseline, participants
were similar in demographic characteris-
tics, glycemic control, diabetes medica-
tions, blood pressure, and lipids (Table
1). Only 13% reported current tobacco
use, and this percentage did not differ be-
tween dietary arms. Baseline differences
in weight between the dietary arms were
adjusted for in the statistical model.
Attrition
Data collection of weight and A1C was
complete for 91% of participants at 3
months(n95),80%ofparticipantsat6
months(n84),and81%ofparticipants
at 12 months (n  85). There was no dif-
ference in attrition between dietary arms.
Weight
Weight change at each time point is
shown in Table 2. After adjustment for
ageandsex,baselinedifferencesinweight
were not signiﬁcant (P  0.149). During
the ﬁrst 3 months, the low-carbohydrate
group lost an average of 1.7 kg/month
(95% CI 1.4–2.0) and in months 3–12
gainedanaverageof0.23kg/month(95%
CI0.09–0.35).Thelow-fatgroupincon-
trast lost weight at a slower rate of 1.2
kg/month (95% CI 0.86–1.5) and pla-
teaued during months 3–12 with an aver-
ageweightgainof0.01kg/month(95%
CI 0.13 to 0.14). At 1 year, there was a
3.4% weight reduction in both groups.
The difference in the early- and late-
phase rates of weight change between the
dietary groups was signiﬁcant (P 
0.005). In a sensitivity analysis that car-
ried forward the baseline weight for miss-
ing values, the ﬁndings were similar.
Glycemic control
Change in A1C at each time is seen in
Table 2. There was no difference in the
rateofchangeinA1Cineithertheearlyor
late phase of dietary intervention. On av-
erage,participantsexperiencedadecrease
inA1Cof0.12permonthduringtheearly
phase (months 0–3) but an increase of
0.06 per month during the late phase
(months 3–12). Participants with higher
baseline A1C levels had more rapid de-
clines in A1C during the ﬁrst 3 months
(r  –0.35, 95% CI –0.11 to –0.55), but
baseline levels did not affect the rate of
change in A1C in months 3–12. There
was an association between medication
changes and A1C such that increases in
insulindoseorsulfonylureadosewereas-
sociated with slightly higher A1C levels.
Oftheparticipantsusinginsulin,thedose
was reduced by a mean  SD of 10  14
unitsinthelow-carbohydratearmandin-
creasedby419unitsinthelow-fatarm
(P  0.12) at 12 months. Of the partici-
pants, 26% of those prescribed sulfonyl-
ureas had a reduction in sulfonylurea
dose at 12 months. The change in sulfo-
nylurea dose was a 1.6  3.6 mg reduc-
tion in both arms. Imputation of baseline
measurements for missing A1C values
yielded similar results.
Table 1—Baseline characteristics of participants
Low-carbohydrate diet Low-fat diet
n 55 50
Age (years) 54  65 3  7
Female sex 45 (82) 37 (74)
Race
Black 34 (62) 33 (66)
Hispanic 8 (15) 9 (18)
White 8 (15) 7 (14)
Asian 2 (4) 1 (2)
Other 2 (4) 0
Physical measures
Weight (kg) 93.6  18 101  19
BMI (kg/m
2) 35  63 7  6
Systolic blood pressure (mmHg) 125  18 130  17
Diastolic blood pressure (mmHg) 73  97 7  10
Clinical
A1C (%) 7.5  1.5 7.4  1.4
Total cholesterol (mmol/l) 4.4  0.83 4.3  0.86
LDL (mmol/l) 2.5  0.69 2.4  0.74
HDL (mmol/l) 1.3  0.24 1.2  0.29
Triglycerides (mmol/l) 1.4  0.84 1.4  0.67
Medications
Metformin 43 (78) 43 (86)
Sulfonylurea 24 (44) 26 (52)
Insulin 19 (35) 12 (24)
Cholesterol-lowering medication 34 (62) 28 (56)
Data are means  SD or n (%) unless otherwise noted.
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Systolic blood pressure and diastolic blood
pressure were similar between dietary
groups at baseline and did not change over
the 12-month period (Table 2).
Lipids
Over12months,therewerenosigniﬁcant
differences in total cholesterol, triglycer-
ides, or calculated LDL between dietary
groups.Therewasasigniﬁcantincreasein
HDL in the low-carbohydrate group,
which occurred at 6 months and was sus-
tained at 12 months (Table 2).
Dietary adherence
At baseline, dietary groups did not differ
with respect to calorie or macronutrient
intake; 43% of calories were from car-
bohydrates, 36% were from fat, and 23%
were from proteins. Based on food
records, at 3 months participants in the
low-carbohydrate arm had an intake of
24% of calories from carbohydrate
(equivalentto7744gofcarbohydrates
daily) and 49% of calories from fat. The
low-fat group had an intake of 53% of
calories from carbohydrate (equivalent to
199  69 g of carbohydrates) and an in-
takeof25%ofcaloriesfromfat.Asseenin
Table 3, at 6 and 12 months, there was an
increaseincaloriesandmacronutrientsin
both groups, suggesting decreased
adherence.
CONCLUSIONS— Our results indi-
cate that after 1 year, overweight patients
with type 2 diabetes had similar weight
reduction with both a low-carbohydrate
andalow-fatdiet.Similartopriorstudies,
we observed a more rapid weight loss af-
ter initiation of a low-carbohydrate diet
and equivalent weight loss after 1 year
(2,3).Despitemodestweightreductionin
botharms,therewasnosigniﬁcantreduc-
tion in A1C. Participants in the low-
carbohydrate arm achieved an initial
meanreductionofA1C0.6%intheﬁrst3
months, but this was not sustained. Prior
studies demonstrated that a 6-kg weight
losswasassociatedwithA1Creductionof
0.55%(22).Studyparticipantsachieveda
3-kg weight loss, which may not have
been sufﬁcient to affect A1C. The lack of
changeinA1Cshouldalsobetakeninthe
context of reduced medications. One-
third of all participants were taking
thiazolidinedione medications before
randomization, which were discontinued
during prerandomization and were not
restarted.Inaddition,therewasanoverall
reduction in insulin and sulfonylurea
dose. Perhaps we would have observed
greater reductions in A1C if we did not
make medication adjustments during the
study; however, because we were con-
cerned about hypoglycemia, not making
adjustments would not have been
appropriate.
The initial difference in weight loss
between arms was similar to that ob-
served previously (2,3). Although there is
debate regarding the effects of macronu-
trient composition on weight loss, it
would appear from our results that par-
ticipants in the low-carbohydrate arm re-
duced their caloric intake to a greater
extent than participants in the low-fat
arm. In addition, low-carbohydrate arm
participants had a greater reduction in in-
sulin dose and because of the potential
effect of insulin on weight gain, this re-
duction may have promoted a greater
weight loss.
Dietary adherence is a key factor in
achievement of weight loss with any diet
(5). Our diverse patient population, 80%
of whom were black or Hispanic, had
high carbohydrate and fat intake at base-
line. Culturally, diets of Hispanics may
have higher amounts of carbohydrate in-
take than those of the general U.S. popu-
lation (23) and following a low-
Table 2—Change in anthropometric and metabolic outcomes at 3, 6, and 12 months after diet initiation
3 months 6 months 12 months P
A1C
Low-carbohydrate diet 0.64  1.4 0.29  0.92 0.02  0.89 0.71
Low-fat diet 0.26  1.1 0.15  1.1 0.24  1.4
Weight (kg)*
Low-carbohydrate diet 5.2  2.8 4.8  3.5 3.1  4.8 0.005
Low-fat diet 3.2  3.7 4.4  5.3 3.1  5.8
Systolic blood pressure (mmHg)
Low-carbohydrate diet 5.8  19.2 0.78  17.7 2.0  15.6 0.15
Low-fat diet 0.98  21.0 37  19.8 1.8  22.6
Diastolic blood pressure (mmHg)
Low-carbohydrate diet 2.2  12.5 0.93  12.4 2.9  9.4 0.62
Low-fat diet 0.40  12.6 0.95  9.8 2.2  11.6
Total cholesterol (mmol/l)†
Low-carbohydrate diet 0.05  0.79 0.10  0.76 0.37
Low-fat diet 0.27  0.74 0.13  0.70
LDL (mmol/l)
Low-carbohydrate diet 0.10  0.52 0.04  0.63 0.23
Low-fat diet 0.25  0.56 0.18  0.66
HDL (mmol/l)
Low-carbohydrate diet 0.16  0.28 0.16  0.27 0.002
Low-fat diet 0.01  0.22 0.06  0.21
Triglycerides (mmol/l)
Low-carbohydrate diet 0.02  0.85 0.15  0.88 0.53
Low-fat diet 0.04  0.56 0.01  0.86
Data are means  SD. *P values for diet difference over all time points. †Lipid values were not collected at 3 months.
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evengreaterchallengeforthispopulation.
We did not observe any change in
blood pressure at 1 year but did observe
an increase in HDL in participants in the
low-carbohydrate arm, which is consis-
tentwithpriorstudies(2,24).Participants
in the low-carbohydrate arm increased
their total and monounsaturated fat in-
take, which may have contributed to this
increase. In contrast with previous stud-
ies, we did not observe signiﬁcant reduc-
tions in triglycerides, which may be due
to low triglyceride levels at baseline.
We did not have outcomes of A1C
and weight for 19% of participants at 12
months. This attrition rate is lower than
that found in many dietary interventions
(13). We analyzed the data, carrying for-
ward baseline values for these missing
outcomes, assuming that any weight lost
during the study was regained. This anal-
ysis did not change our results. However,
if participants withdrew because they
gained weight beyond their baseline
weight, then our weight results would be
less favorable.
Several limitations should be consid-
ered in interpreting our ﬁndings. Despite
randomization,participantsinthelow-fat
armwereheavieratbaselinethanthosein
the low-carbohydrate arm. Although we
controlled for this imbalance statistically,
it raises the question of whether there
were other unmeasured differences be-
tween the arms. We used single-day di-
etary recall or a single-day food record to
assess dietary intake, either of which is
subject to bias. Participants may not have
fully recalled their dietary intake and, in
addition, may have changed their dietary
intake for the day before their scheduled
appointment. We did not have objective
measures of physical activity, which
could be a confounder; however, given
the similarity of our ﬁndings in both
groups at 1 year, it is unlikely that there
weresigniﬁcantchangesinphysicalactiv-
ity in either group.
In conclusion, our study demon-
strates that among overweight patients
with type 2 diabetes, there was no signif-
icant difference in the weight or A1C
change in participants after a low-
carbohydrate compared with a low-fat
diet for 12 months. Participants in both
armsachievedanaverage3.4%weightre-
duction but did not reduce A1C. Differ-
encesintheshort-termeffectsofeachdiet
were not sustained.
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Table 3—Dietary intake at each time point
Baseline 6 months* 12 months†
Caloric intake (kcal/day)
Low-carbohydrate diet 1,983  650 1,652  650 1,642  600
Low-fat diet 1,863  450 1,653  471 1,810  590
P value for low-carbohydrate diet vs. low-fat diet 0.28 0.99 0.30
Carbohydrate intake (% total energy)
Low-carbohydrate diet 43.9  9.1 33.5  14.7 33.4  13.2
Low-fat diet 41.2  10.4 48.1  14.1 50.1  10.0
P value for low-carbohydrate diet vs. low-fat diet 0.14 0.001 0.001
Fat intake (% total energy)
Low-carbohydrate diet 36.1  7.6 43.0  13.1 43.9  10.8
Low-fat diet 38.8  9.4 30.8  9.8 30.8  10.2
P value for low-carbohydrate diet vs. low-fat diet 0.12 0.001 0.001
Saturated fat (% total fat)†
Low-carbohydrate diet 31.3  7.9 28.6  8.8 28.7  9.6
Low-fat diet 31.5  7.0 30.7  8.4 30.2  5.4
P value for low-carbohydrate diet vs. low-fat diet 0.91 0.33 0.43
Polyunsaturated fat (% total fat)†
Low-carbohydrate diet 19.1  7.6 19.1  7.5 17.4  8.0
Low-fat diet 19.6  9.0 19.8  8.0 21.4  8.6
P value for low-carbohydrate diet vs. low-fat diet 0.76 0.70 0.06
Monounsaturated fat (% total fat)†
Low-carbohydrate diet 36.1  7.0 39.5  11.0 40.7  10.4
Low-fat diet 37.6  6.9 35.2  8.7 38.1  6.9
P value for low-carbohydrate diet vs. low-fat diet 0.28 0.08 0.25
Protein intake (% total energy)
Low-carbohydrate diet 19.5  6.3 22.5  6.0 22.7  6.7
Low-fat diet 19.4  6.6 20.5  7.0 18.9  4.7
P value for low-carbohydrate diet vs. low-fat diet 0.94 0.18 0.02
Fiber (g/day)
Low-carbohydrate diet 15.4  8.5 12.6  10.7 15.1  9.5
Low-fat diet 14.9  8.5 17.0  9.7 17.2  8.1
P value for low-carbohydrate diet vs. low-fat diet 0.78 0.09 0.36
Data are means  SD. *Based on 24-h recall from 68 participants. †Based on 24-h recall from 57 participants.
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